Kura Oncology Says Darlifarnib Plus Cabozantinib Shows 44% ORR And 94% DCR In Cabozantinib-Pretreated ccRCC Patients In FIT-001 Study

Benzinga Newsdesk www.benzinga.com Positive 81.0%